Senzime introduces new graphical profile

Uppsala, October 3, 2016. Senzime AB (publ.) changes graphic profile. Following the acquisition and integration of Acacia Designs BV, a new graphical profile is introduced to reflect the new Senzime - a company at the forefront of patient monitoring.

In May 2016, Senzime acquired Acacia Designs BV (Acacia), an international development company within anesthesia monitoring originating from research conducted at Mayo Clinic, USA. Acacia has developed a new way to monitor the progress of anesthesia and reduce complications in patients undergoing surgery. The merger of Senzime’s and Acacia’s businesses creates a company with a broad and unique offering of systems and products that continuously monitor biological and physiological processes in patients during and after surgery.

"The new Senzime offers a wider and more complete range of products for the healthcare market. In order to reflect our broader product portfolio and view of the new Senzime, we have changed the graphic profile” says Lena Söderström, CEO of Senzime.

Visit our webpage www.senzime.com to take part of the new changes.

For further information, please contact:

Lena Söderström, CEO of Senzime AB
Tel: +46 708-16 39 12, email: lena.soderstrom@senzime.com

TO THE EDITORS

About Senzime

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of $10 billion. The company's shares are listed on AktieTorget (ATORG: SEZI) www.senzime. com

About Us

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com

Subscribe

Documents & Links